Revenue
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2021
2022
2023
2024
2025
Anixa Biosciences Inc (ANIX)
Price$3.07Cached quote
Net income
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2010
2011
2012
2014
2015
2016
2017
2018
2019
2020
Total cash / debt
CashTotal debt
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $210,000 | $210,000 | $0 | $512,000 | — | $250,000 | $1.1M | $362,500 | $300,000 | $9.3M | $3.7M | $388,850 | $940,010 | $1.0M | $730,675 |
| Gross profit | — | $0 | $49,000 | $0 | $127,000 | — | — | — | — | — | — | — | — | $936,137 | $969,112 | $648,368 |
| Gross margin | — | 0.00% | 23.33% | — | 24.80% | — | — | — | — | — | — | — | — | 99.59% | 96.60% | 88.74% |
| Research & development | $5.1M | $6.4M | $4.8M | $6.7M | $6.2M | $4.4M | $5.5M | $6.8M | $1.6M | $1.6M | $711,391 | — | — | $2.2M | $3.1M | $3.0M |
| Operating expenses | $7.9M | $9.0M | $11.2M | $7.2M | $13.6M | $5.8M | $12.1M | $15.4M | $6.4M | $4.8M | $10.2M | $8.7M | $8.3M | $5.1M | $6.0M | $6.0M |
| Operating income | −$11.7M | −$13.8M | −$11.0M | −$13.9M | −$13.1M | −$10.0M | −$11.9M | −$14.3M | −$6.1M | −$4.5M | −$944,759 | −$5.0M | −$7.9M | −$4.1M | −$5.0M | −$5.2M |
| Operating margin | — | −6,586.19% | −5,243.33% | — | −2,565.63% | — | −4,756.00% | −1,284.41% | −1,676.02% | −1,503.00% | −10.21% | −137.54% | −2,036.17% | −439.84% | −501.23% | −718.27% |
| EBITDA | −$11.7M | −$13.8M | −$11.0M | −$13.8M | — | −$9.9M | −$11.4M | −$14.3M | −$6.0M | −$4.5M | −$932,244 | — | — | −$4.1M | −$5.0M | −$5.2M |
| EBITDA margin | — | −6,568.57% | −5,221.43% | — | — | — | −4,569.48% | −1,282.75% | −1,664.10% | −1,491.89% | −10.07% | — | — | −439.07% | −500.43% | −717.13% |
| Net income | −$10.9M | −$12.6M | −$9.8M | −$13.6M | −$13.0M | −$10.0M | −$11.6M | −$14.0M | −$5.0M | −$5.0M | −$1.4M | −$9.6M | −$10.1M | −$4.3M | −$7.4M | −$5.2M |
| Net profit margin | — | −5,978.10% | −4,671.90% | — | −2,530.08% | — | −4,658.82% | −1,258.07% | −1,381.79% | −1,672.14% | −14.90% | −261.94% | −2,592.28% | −452.42% | −735.46% | −708.27% |
| Basic EPSper basic share | -$0.34 | -$0.39 | -$0.32 | $0.45 | -$0.45 | -$0.45 | -$0.59 | -$0.79 | -$0.58 | -$0.57 | -$0.16 | -$1.10 | -$1.25 | -$0.50 | -$1.00 | -$0.75 |
| Diluted EPSper diluted share | -$0.34 | -$0.39 | -$0.32 | $0.45 | -$0.45 | -$0.45 | -$0.59 | -$0.79 | -$0.58 | -$0.57 | -$0.16 | -$1.10 | -$1.25 | -$0.50 | -$1.00 | -$0.75 |
Owners
Reported shareholders
≈3.91%of listed shares
VANGUARD CAPITAL MANAGEMENT LLC1.33M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
VANGUARD CAPITAL MANAGEMENT LLC | ≈3.91%1.33M shares |
Titterton Lewis H jr | ≈2.86%972.17K shares |
KUMAR AMIT | ≈1.85%630.81K shares |
UBS Group AG | ≈1.72%585.43K shares |
Laird Norton Wetherby Trust Company, LLC | ≈1.70%578.73K shares |
D.A. DAVIDSON & CO. | ≈1.59%539.27K shares |
GEODE CAPITAL MANAGEMENT, LLC | ≈1.06%359.19K shares |
MARSHALL WACE, LLP | ≈0.97%328.33K shares |
BlackRock, Inc. | ≈0.59%199.76K shares |
VANGUARD FIDUCIARY TRUST CO | ≈0.57%192.36K shares |
STATE STREET CORP | ≈0.47%159.04K shares |
Baskies Arnold M | ≈0.40%135K shares |
GSA CAPITAL PARTNERS LLP | ≈0.35%117.47K shares |
LPL Financial LLC | ≈0.33%111.54K shares |
NORTHERN TRUST CORP | ≈0.20%69.24K shares |
RENAISSANCE TECHNOLOGIES LLC | ≈0.17%59.37K shares |
CoreCap Advisors, LLC | ≈0.15%52.02K shares |
Bank of New York Mellon Corp | ≈0.14%47.44K shares |
Catelani Michael | ≈0.13%44.5K shares |
Westside Investment Management, Inc. | ≈0.13%43K shares |
Percentages use 34.02M shares of this listed class outstanding on Jun 10, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 16, 2026Form 4 | Titterton Lewis H jrDirector | BuyCommon Stock | 2.8K | $2.64 | $7.5K | 972.2K |
| Jun 12, 2026Form 4 | KUMAR AMITChief Executive Officer | BuyCommon Stock | 21.0K | $2.50 | $52.5K | 630.8K |
| Jan 28, 2026Form 4 | Baskies Arnold MDirector | BuyCommon Stock | 10.0K | $3.04 | $30.4K | 135.0K |
| Jul 31, 2025Form 4 | Titterton Lewis H jrDirector | BuyCommon Stock | 10.0K | $3.08 | $30.8K | 953.3K |
| Jul 30, 2025Form 4 | KUMAR AMITChief Executive Officer | BuyCommon Stock | 5.0K | $3.16 | $15.8K | 579.9K |